# IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/irb-continuing-review-after-clinical-investigation-approval-guidance-for-irbs-clinical-investigators-and-sponsors/7c18de8c-1544-4b72-a67a-3a861d29c31c

> FDA guidance document: IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors. Issue date: February 27, 2012. Get complete insights and analysis.

---

## Details

- Title: IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2012-02-27
- Last Changed: 2020-04-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2009-D-0605">FDA-2009-D-0605</a>

## Related Documents

- [IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors](https://www.globalkeysolutions.net/guidances/guidance-document/irb-responsibilities-for-reviewing-the-qualifications-of-investigators-adequacy-of-research-sites-and-the-determination-of-whether-an-indide-is-needed-guidance-for-irbs-clinical-investigators-and-sponsors/797294db-f9b3-4c0d-b100-f6ee4b81ebae)
- [Considerations When Transferring Clinical Investigation Oversight to Another IRB:  Guidance for IRBs, Clinical Investigators, and Sponsors](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-when-transferring-clinical-investigation-oversight-to-another-irb-guidance-for-irbs-clinical-investigators-and-sponsors/fe8296e5-3ca7-4209-9920-27aa4635ee35)
- [Q11 Development and Manufacture of Drug Substances](https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances/8d1aacb1-7da4-42f7-9a3a-18b2fc871411)